CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation

Immunity

Volumn 44, Issue 2, 2016, Pages 303-315

  Kumar, Vinit ^a   Cheng, Pingyan ^b   Condamine, Thomas ^a   Mony, Sridevi ^a   Languino, Lucia R ^c   McCaffrey, Judith C ^b   Hockstein, Neil ^d   Guarino, Michael ^d   Masters, Gregory ^d   Penman, Emily ^d   Denstman, Fred ^d   Xu, Xiaowei ^e   Altieri, Dario C ^a   Du, Hong ^f   Yan, Cong ^f   Gabrilovich, Dmitry I ^a  

^a WISTAR INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d HELEN F GRAHAM CANCER CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; PHOSPHATASE; SIALIC ACID DERIVATIVE; STAT3 PROTEIN;

ANIMAL; BAGG ALBINO MOUSE; BONE MARROW CELL; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CELL MOTION; DIMERIZATION; FEMALE; GENETICS; HYPOXIA; IMMUNOLOGY; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; MOUSE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD45; CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; DIMERIZATION; FEMALE; HYPOXIA; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID CELLS; PHOSPHORIC MONOESTER HYDROLASES; SIALIC ACIDS; STAT3 TRANSCRIPTION FACTOR; TUMOR MICROENVIRONMENT;

EID: 84958652204     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2016.01.014     Document Type: Article

References (41)

1. Abad C., Nobuta H., Li J., Kasai A., Yong W.H., Waschek J.A. Targeted STAT3 disruption in myeloid cells alters immunosuppressor cell abundance in a murine model of spontaneous medulloblastoma. J. Leukoc. Biol. 2014, 95:357-367.
2. Bain C.C., Bravo-Blas A., Scott C.L., Gomez Perdiguero E., Geissmann F., Henri S., Malissen B., Osborne L.C., Artis D., Mowat A.M. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat. Immunol. 2014, 15:929-937.
3. Bharadwaj U., Li M., Zhang R., Chen C., Yao Q. Elevated interleukin-and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res. 2007, 67:5479-5488.
4. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., Sebti S.M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003, 63:1270-1279.
5. Corzo C.A., Condamine T., Lu L., Cotter M.J., Youn J.I., Cheng P., Cho H.I., Celis E., Quiceno D.G., Padhya T., et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 2010, 207:2439-2453.
6. Doedens A.L., Stockmann C., Rubinstein M.P., Liao D., Zhang N., DeNardo D.G., Coussens L.M., Karin M., Goldrath A.W., Johnson R.S. Macrophage expression of hypoxia-inducible factor-alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010, 70:7465-7475.
7. Franklin R.A., Liao W., Sarkar A., Kim M.V., Bivona M.R., Liu K., Pamer E.G., Li M.O. The cellular and molecular origin of tumor-associated macrophages. Science 2014, 344:921-925.
8. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
9. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
10. Galdiero M.R., Garlanda C., Jaillon S., Marone G., Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J. Cell. Physiol. 2013, 228:1404-1412.
11. Hasita H., Komohara Y., Okabe H., Masuda T., Ohnishi K., Lei X.F., Beppu T., Baba H., Takeya M. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 2010, 101:1913-1919.
12. Herrmann A., Kortylewski M., Kujawski M., Zhang C., Reckamp K., Armstrong B., Wang L., Kowolik C., Deng J., Figlin R., Yu H. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res. 2010, 70:7455-7464.
13. Holmes N. CD45: all is not yet crystal clear. Immunology 2006, 117:145-155.
14. Kaplan-Lefko P.J., Chen T.M., Ittmann M.M., Barrios R.J., Ayala G.E., Huss W.J., Maddison L.A., Foster B.A., Greenberg N.M. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003, 55:219-237.
15. Kato M., Takahashi M., Akhand A.A., Liu W., Dai Y., Shimizu S., Iwamoto T., Suzuki H., Nakashima I. Transgenic mouse model for skin malignant melanoma. Oncogene 1998, 17:1885-1888.
16. Ko J.S., Rayman P., Ireland J., Swaidani S., Li G., Bunting K.D., Rini B., Finke J.H., Cohen P.A. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010, 70:3526-3536.
17. Komohara Y., Ohnishi K., Kuratsu J., Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 2008, 216:15-24.
18. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., Niu G., Kay H., Mulé J., Kerr W.G., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 2005, 11:1314-1321.
19. Kujawski M., Kortylewski M., Lee H., Herrmann A., Kay H., Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 2008, 118:3367-3377.
20. Meyer C., Sevko A., Ramacher M., Bazhin A.V., Falk C.S., Osen W., Borrello I., Kato M., Schadendorf D., Baniyash M., Umansky V. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc. Natl. Acad. Sci. USA 2011, 108:17111-17116.
21. Nefedova Y., Huang M., Kusmartsev S., Bhattacharya R., Cheng P., Salup R., Jove R., Gabrilovich D. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 2004, 172:464-474.
22. Nefedova Y., Cheng P., Gilkes D., Blaskovich M., Beg A.A., Sebti S.M., Gabrilovich D.I. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J. Immunol. 2005, 175:4338-4346.
23. Nefedova Y., Nagaraj S., Rosenbauer A., Muro-Cacho C., Sebti S.M., Gabrilovich D.I. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005, 65:9525-9535.
24. Noy R., Pollard J.W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014, 41:49-61.
25. Park S.J., Nakagawa T., Kitamura H., Atsumi T., Kamon H., Sawa S., Kamimura D., Ueda N., Iwakura Y., Ishihara K., et al. IL-regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol. 2004, 173:3844-3854.
26. Rébé C., Végran F., Berger H., Ghiringhelli F. STAT3 activation: A key factor in tumor immunoescape. JAK-STAT 2013, 2:e23010.
27. Schulz C., Gomez Perdiguero E., Chorro L., Szabo-Rogers H., Cagnard N., Kierdorf K., Prinz M., Wu B., Jacobsen S.E., Pollard J.W., et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012, 336:86-90.
28. Shand F.H., Ueha S., Otsuji M., Koid S.S., Shichino S., Tsukui T., Kosugi-Kanaya M., Abe J., Tomura M., Ziogas J., Matsushima K. Tracking of intertissue migration reveals the origins of tumor-infiltrating monocytes. Proc. Natl. Acad. Sci. USA 2014, 111:7771-7776.
29. Shim S.H., Sung M.W., Park S.W., Heo D.S. Absence of STAT1 disturbs the anticancer effect induced by STAT3 inhibition in head and neck carcinoma cell lines. Int. J. Mol. Med. 2009, 23:805-810.
30. Solito S., Bronte V., Mandruzzato S. Antigen specificity of immune suppression by myeloid-derived suppressor cells. J. Leukoc. Biol. 2010, 90:31-36.
31. Stark G.R., Darnell J.E. The JAK-STAT pathway at twenty. Immunity 2012, 36:503-514.
32. Sun Z., Yao Z., Liu S., Tang H., Yan X. An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer. Immunobiology 2006, 211:199-209.
33. Trikha P., Carson W.E. Signaling pathways involved in MDSC regulation. Biochim. Biophys. Acta 2014, 1846:55-65.
34. Tu S.P., Jin H., Shi J.D., Zhu L.M., Suo Y., Lu G., Liu A., Wang T.C., Yang C.S. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev. Res. (Phila.) 2012, 5:205-215.
35. Vasquez-Dunddel D., Pan F., Zeng Q., Gorbounov M., Albesiano E., Fu J., Blosser R.L., Tam A.J., Bruno T., Zhang H., et al. STAT3 regulates arginase-in myeloid-derived suppressor cells from cancer patients. J. Clin. Invest. 2013, 123:1580-1589.
36. Wu L., Bijian K., Shen S.H. CD45 recruits adapter protein DOK-and negatively regulates JAK-STAT signaling in hematopoietic cells. Mol. Immunol. 2009, 46:2167-2177.
37. Xin H., Zhang C., Herrmann A., Du Y., Figlin R., Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009, 69:2506-2513.
38. Xu Z., Weiss A. Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms. Nat. Immunol. 2002, 3:764-771.
39. Yan C., Qu P., Du H. Myeloid-specific expression of Stat3C results in conversion of bone marrow mesenchymal stem cells into alveolar type II epithelial cells in the lung. Sci. China Life Sci. 2012, 55:576-590.
40. Yin J., Hashimoto A., Izawa M., Miyazaki K., Chen G.Y., Takematsu H., Kozutsumi Y., Suzuki A., Furuhata K., Cheng F.L., et al. Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res. 2006, 66:2937-2945.
41. Yu H., Lee H., Herrmann A., Buettner R., Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 2014, 14:736-746.